Nathan Kobrinsky is an Oncology physician. OpenAlex indexes 87 publications with 3,878 citations (h-index 28).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2101 Elm Street N
Fargo, ND 58102
Telephone
701-239-3700Registry record last updated 23 Jun 2025.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eisai Inc.Program year20231 payment
- Alexion Pharmaceuticals, Inc.Program year20221 payment
- Horizon Therapeutics plcProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
27%Statin9.6%Rosuvastatin Calcium76%Atorvastatin Calcium25%Part D<11 patientsCalcium channel blocker8.4%Amlodipine Besylate84%Amlodipine-Valsartan-Hctz16%Part D<11 patients+ 4 more classes in this area
Blood & clotting
25.8%Factor Xa inhibitor22.7%Eliquis77%Xarelto23%Part D<11 patientsSalt solutions1.7%Sodium Chloride100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
16.9%Serotonin-3 Receptor Antagonist3.9%Ondansetron Hcl55%Ondansetron Odt45%Part D<11 patientsProton pump inhibitor3.6%Pantoprazole Sodium63%Omeprazole37%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Neonatal hemophagocytic lymphohistiocytosis: A meta‐analysis of 205 cases
Pediatric Blood & Cancer
2024 - A Validation Study of the Alcohol Related Neurodevelopmental Disorders Behavioral Checklist
Alcoholism Clinical and Experimental Research
2021 - Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement
Journal of Thrombosis and Haemostasis
2018 - Timing and severity of inhibitor development in recombinant versus plasma‐derived factor VIII concentrates: a SIPPET analysis
Journal of Thrombosis and Haemostasis
2017 - Phase I trial of low-dose interleukin 2 therapy in patients with Wiskott-Aldrich syndrome
Clinical Immunology
2017
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”